Betamethasone latency period and neonatal hypoglycemia in term infants
Introduction Infants exposed to antenatal betamethasone (BMZ) between 34.0 and 36.6 weeks gestational age (GA) have increased risk for neonatal hypoglycemia, a known cause of brain injury. While a shorter latency period between BMZ administration and delivery is associated with an increased risk of...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | The Journal of Maternal-Fetal & Neonatal Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14767058.2025.2540477 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849343514264993792 |
|---|---|
| author | Lauren A. Buckley Briana Clifton Katelyn M. Tessier Connor Demorest Raghavendra B. Rao Sarah A. Wernimont |
| author_facet | Lauren A. Buckley Briana Clifton Katelyn M. Tessier Connor Demorest Raghavendra B. Rao Sarah A. Wernimont |
| author_sort | Lauren A. Buckley |
| collection | DOAJ |
| description | Introduction Infants exposed to antenatal betamethasone (BMZ) between 34.0 and 36.6 weeks gestational age (GA) have increased risk for neonatal hypoglycemia, a known cause of brain injury. While a shorter latency period between BMZ administration and delivery is associated with an increased risk of neonatal hypoglycemia in late preterm infants, the impact of the BMZ latency period on neonatal hypoglycemia in infants born at term (≥37 weeks) has not been previously characterized. Term infants without additional risk factors such as growth restriction or maternal diabetes are not routinely screened and may be at risk for unrecognized neonatal hypoglycemia. The purpose of this study was to determine whether the latency period from antenatal BMZ administration to delivery impacts the incidence of neonatal hypoglycemia in term infants.Methods This retrospective cohort study analyzed maternal–infant dyads from the University of Minnesota Obstetric Measures database (January 2017–August 2023) who received BMZ during pregnancy and delivered at ≥37 weeks (N = 758). The primary outcome was incidence of early neonatal hypoglycemia, defined as a blood glucose level <40 mg/dL within 48 h of birth, in neonates exposed to BMZ <14 days (recent BMZ; N = 161) vs. >14 days (remote BMZ; N = 597) prior to delivery. Secondary outcomes included incidence of severe neonatal hypoglycemia (blood glucose level <25 mg/dL within 48 h of birth) and treatment for neonatal hypoglycemia with dextrose gel or IV dextrose. Demographics, pregnancy characteristics, neonatal characteristics, and outcomes were summarized by time from last dose of BMZ to delivery.Results The most common indication for BMZ was pre-eclampsia/pregnancy-induced hypertension in the recent BMZ group and preterm labor with intact membranes in the remote BMZ group (p < .001). Maternal diabetes status did not differ between groups. The recent BMZ group had lower median GA at birth (37.1 vs. 38.4 weeks, p < .001) and lower birth weight (3.03 vs. 3.29 kg, p < .001). The percentage of neonates classified as small for GA or large for GA was similar between groups. Approximately 30% of the neonates had a documented glucose measurement within 48 h of birth. The incidence of early neonatal hypoglycemia, severe hypoglycemia, and treatment for hypoglycemia with dextrose gel or IV dextrose did not differ between infants exposed to recent BMZ vs. those exposed to remote BMZ.Discussion In this cohort of term infants, a shorter latency period between BMZ administration and delivery was not associated with increased incidence or treatment of hypoglycemia. However, the rate of hypoglycemia screening was low in both groups and rates of undiagnosed hypoglycemia in BMZ-exposed term neonates remain unknown. Prospective longitudinal studies aimed at characterizing the risk of hypoglycemia in term infants exposed to BMZ would be beneficial to inform hypoglycemia screening practices in BMZ-exposed neonates. |
| format | Article |
| id | doaj-art-1ee3f4d583584600832ccea55fec5b70 |
| institution | Kabale University |
| issn | 1476-7058 1476-4954 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | The Journal of Maternal-Fetal & Neonatal Medicine |
| spelling | doaj-art-1ee3f4d583584600832ccea55fec5b702025-08-20T03:42:57ZengTaylor & Francis GroupThe Journal of Maternal-Fetal & Neonatal Medicine1476-70581476-49542025-12-0138110.1080/14767058.2025.2540477Betamethasone latency period and neonatal hypoglycemia in term infantsLauren A. Buckley0Briana Clifton1Katelyn M. Tessier2Connor Demorest3Raghavendra B. Rao4Sarah A. Wernimont5Department of Pediatrics, Division of Neonatology, University of Minnesota, Minneapolis, MN, USADepartment of Obstetrics, Gynecology and Women’s Health, University of Minnesota, Minneapolis, MN, USAMasonic Cancer Center Biostatistics Core, University of Minnesota, Minneapolis, MN, USAMasonic Cancer Center Biostatistics Core, University of Minnesota, Minneapolis, MN, USADepartment of Pediatrics, Division of Neonatology, University of Minnesota, Minneapolis, MN, USADepartment of Obstetrics, Gynecology and Women’s Health, University of Minnesota, Minneapolis, MN, USAIntroduction Infants exposed to antenatal betamethasone (BMZ) between 34.0 and 36.6 weeks gestational age (GA) have increased risk for neonatal hypoglycemia, a known cause of brain injury. While a shorter latency period between BMZ administration and delivery is associated with an increased risk of neonatal hypoglycemia in late preterm infants, the impact of the BMZ latency period on neonatal hypoglycemia in infants born at term (≥37 weeks) has not been previously characterized. Term infants without additional risk factors such as growth restriction or maternal diabetes are not routinely screened and may be at risk for unrecognized neonatal hypoglycemia. The purpose of this study was to determine whether the latency period from antenatal BMZ administration to delivery impacts the incidence of neonatal hypoglycemia in term infants.Methods This retrospective cohort study analyzed maternal–infant dyads from the University of Minnesota Obstetric Measures database (January 2017–August 2023) who received BMZ during pregnancy and delivered at ≥37 weeks (N = 758). The primary outcome was incidence of early neonatal hypoglycemia, defined as a blood glucose level <40 mg/dL within 48 h of birth, in neonates exposed to BMZ <14 days (recent BMZ; N = 161) vs. >14 days (remote BMZ; N = 597) prior to delivery. Secondary outcomes included incidence of severe neonatal hypoglycemia (blood glucose level <25 mg/dL within 48 h of birth) and treatment for neonatal hypoglycemia with dextrose gel or IV dextrose. Demographics, pregnancy characteristics, neonatal characteristics, and outcomes were summarized by time from last dose of BMZ to delivery.Results The most common indication for BMZ was pre-eclampsia/pregnancy-induced hypertension in the recent BMZ group and preterm labor with intact membranes in the remote BMZ group (p < .001). Maternal diabetes status did not differ between groups. The recent BMZ group had lower median GA at birth (37.1 vs. 38.4 weeks, p < .001) and lower birth weight (3.03 vs. 3.29 kg, p < .001). The percentage of neonates classified as small for GA or large for GA was similar between groups. Approximately 30% of the neonates had a documented glucose measurement within 48 h of birth. The incidence of early neonatal hypoglycemia, severe hypoglycemia, and treatment for hypoglycemia with dextrose gel or IV dextrose did not differ between infants exposed to recent BMZ vs. those exposed to remote BMZ.Discussion In this cohort of term infants, a shorter latency period between BMZ administration and delivery was not associated with increased incidence or treatment of hypoglycemia. However, the rate of hypoglycemia screening was low in both groups and rates of undiagnosed hypoglycemia in BMZ-exposed term neonates remain unknown. Prospective longitudinal studies aimed at characterizing the risk of hypoglycemia in term infants exposed to BMZ would be beneficial to inform hypoglycemia screening practices in BMZ-exposed neonates.https://www.tandfonline.com/doi/10.1080/14767058.2025.2540477Antenatalbetamethasonecorticosteroidglucosehypoglycemia |
| spellingShingle | Lauren A. Buckley Briana Clifton Katelyn M. Tessier Connor Demorest Raghavendra B. Rao Sarah A. Wernimont Betamethasone latency period and neonatal hypoglycemia in term infants The Journal of Maternal-Fetal & Neonatal Medicine Antenatal betamethasone corticosteroid glucose hypoglycemia |
| title | Betamethasone latency period and neonatal hypoglycemia in term infants |
| title_full | Betamethasone latency period and neonatal hypoglycemia in term infants |
| title_fullStr | Betamethasone latency period and neonatal hypoglycemia in term infants |
| title_full_unstemmed | Betamethasone latency period and neonatal hypoglycemia in term infants |
| title_short | Betamethasone latency period and neonatal hypoglycemia in term infants |
| title_sort | betamethasone latency period and neonatal hypoglycemia in term infants |
| topic | Antenatal betamethasone corticosteroid glucose hypoglycemia |
| url | https://www.tandfonline.com/doi/10.1080/14767058.2025.2540477 |
| work_keys_str_mv | AT laurenabuckley betamethasonelatencyperiodandneonatalhypoglycemiainterminfants AT brianaclifton betamethasonelatencyperiodandneonatalhypoglycemiainterminfants AT katelynmtessier betamethasonelatencyperiodandneonatalhypoglycemiainterminfants AT connordemorest betamethasonelatencyperiodandneonatalhypoglycemiainterminfants AT raghavendrabrao betamethasonelatencyperiodandneonatalhypoglycemiainterminfants AT sarahawernimont betamethasonelatencyperiodandneonatalhypoglycemiainterminfants |